← Back to Search

Local Anesthetic

ESPB Solutions for Breast Cancer

Phase 2
Waitlist Available
Research Sponsored by Tufts Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare pain scores of two different methods of pain management for subjects undergoing bilateral surgical intervention for breast cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 72 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pain Score at 48 hours
Secondary study objectives
Pain Scores at 6, 12, 18, 24, 30, 38, 42, and 72 hours

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: ControlActive Control1 Intervention
Control arm will receive standard of care solution for the ESPB block
Group II: Liposomal BupivicaineActive Control1 Intervention
Liposomal Bupivicaine arm will receive Liposomal Bupivicaine for the ESPB block

Find a Location

Who is running the clinical trial?

Tufts Medical CenterLead Sponsor
263 Previous Clinical Trials
264,263 Total Patients Enrolled
3 Trials studying Breast Cancer
51 Patients Enrolled for Breast Cancer

Media Library

Liposomal bupivacaine (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT04603911 — Phase 2
Breast Cancer Research Study Groups: Control, Liposomal Bupivicaine
Breast Cancer Clinical Trial 2023: Liposomal bupivacaine Highlights & Side Effects. Trial Name: NCT04603911 — Phase 2
Liposomal bupivacaine (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04603911 — Phase 2
~15 spots leftby Dec 2025